Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Avelumab and axitinib for the treatment of advanced RCC

Toni K. Choueiri, MD, from the Dana-Farber/Brigham and Women’s Hospital, Boston, MA, gives us an insight into the difficulties in choosing to pursue either avelumab or axitinib as therapy for advanced renal cell carcinoma, as evaluated in a Phase Ib trial (NCT02493751), mainly due to their similarities in the degrees of toxicity and efficacy. A few suggestions on what should be done in the future are noted by him, although he states that this will be a hard choice overall. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.